← All sectors / The AI transformation
073 · Genomics & sequencing
Reading biology at cost
Curve position
Binding constraint
Clinical interpretation and reimbursement, not the cost of the read.
Why this sector sits at Orbit
We are moving genomics and sequencing to Orbit. Short-read sequencing is established in research and increasingly in hospitals and clinics, and the market leader is clear. Competition is now on cost per genome, clinical uses and execution rather than on access.
Illumina, the sector's dominant supplier, reported 2025 revenue of about $4.34 billion, flat on 2024. In its Q2 2026 results it raised full-year guidance to $4.60–4.64 billion, roughly 6–7% growth, and said clinical demand for its NovaSeq X sequencer is rising. That is a recovery to a steady rate, not the fast compounding and rush of capital that define Flight.
We would look again if clinical demand pushed the group back into double-digit, accelerating growth. We did not check smaller companies' results this session.
Reviewed on a two month cycle. The position moves only when a dated, verifiable change in the binding constraint justifies it.
Heatmap / How this sector's stocks are moving
| Stock | Price | 1 Day | 1 Week | 1 Month | Year to date |
|---|---|---|---|---|---|
| $ILMN | $226.54 | −4.90% | −21.56% | −17.18% | +72.72% |
| $PACB | $2.55 | +4.51% | −9.89% | −5.56% | +36.36% |
| $TEM | $75.61 | −2.81% | −1.31% | +5.04% | +28.04% |
| $GH | $168.58 | −3.67% | −7.67% | −1.24% | +65.05% |
| $NTRA | $391.03 | +0.62% | −7.87% | −2.40% | +70.69% |
| Sector average | −1.25% | −9.66% | −4.27% | +54.57% |
Prices as of November 5, 2026. The sector's move is the equal-weighted average of these listed companies, a market proxy for context, not recommendations. See it on the full heatmap →
Sentiment / The mood in this sector's stocks
Since 2018, Genomics & sequencing has been in Skepticism and steady 16 separate times. After those, its stocks beat their usual three months 7 times (44%), by a median of −0.8 points.
Confidence: low, a split like this is common by chance, so no edge is called.
Sequencing a genome went from a national project to a routine test in twenty years. The cost curve has largely done its work, and the binding constraint is now interpretation: knowing what a variant means and whether anyone will pay to act on it.
Historically the industry sold instruments and consumables into research budgets, which are grant dependent and cyclical. The shift toward clinical use changes the customer, the regulatory burden, and the revenue durability.
The structural driver is clinical utility expanding beyond rare disease. Oncology profiling, prenatal screening, pharmacogenomics, and increasingly population screening all create recurring test volume with reimbursement attached.
The technology layer spans sequencing instruments and their consumables, sample preparation, long read platforms that resolve structures short reads miss, single cell and spatial methods, and the interpretation software that turns variants into reports.
Adoption economics favor consumables. Instruments are sold once; the flow cells, reagents, and kits recur with every sample, which is where the durable revenue sits.
The beneficiaries include sequencing platform companies, consumables and reagent suppliers, sample preparation and automation vendors, clinical laboratories running tests at volume, and the bioinformatics firms doing interpretation.
The value chain runs from instruments and consumables through laboratory operations to clinical reporting and reimbursement. Consumables pull through is the metric that matters.
The overlooked layer includes reagent and consumables manufacturers, laboratory automation suppliers, specialty clinical labs in specific indications, and the variant interpretation software vendors.
Competitive dynamics have opened up after years of single vendor dominance, with new platforms competing on cost per gigabase and read length, which pressures pricing across the industry.
Risks: instrument pricing competition compresses margins, research funding is cyclical, reimbursement for new tests is slow and contested, and the sector has repeatedly disappointed on the pace of clinical adoption.
What to watch: consumables revenue growth relative to instrument placements, reimbursement decisions for new indications, clinical test volumes, and platform pricing competition.